Kiniksa Pharmaceuticals International (KNSA) Cash & Equivalents (2017 - 2026)

Kiniksa Pharmaceuticals International has reported Cash & Equivalents for 10 years, with the latest figure at $190.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 29.21% year-over-year to $190.0 million; the trailing twelve-month figure through Mar 2026 stood at $190.0 million (down 29.21% YoY), and the FY2025 full-year result was $165.6 million, down 9.8% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $190.0 million, up from $165.6 million in the prior quarter.
• The five-year high for Cash & Equivalents was $268.3 million in Q1 2025, with the low at $80.6 million in Q1 2023.
• Historically, Cash & Equivalents has averaged $167.2 million across 5 years, with a median of $174.9 million in 2025.
• Annual changes were most pronounced in 2022 — Cash & Equivalents plunged 44.86% — and 2024, when it soared 94.34%.
• Kiniksa Pharmaceuticals International's Cash & Equivalents stood at $122.7 million in 2022, then decreased by 12.03% to $108.0 million in 2023, then surged by 70.05% to $183.6 million in 2024, then fell by 9.8% to $165.6 million in 2025, then climbed by 14.71% to $190.0 million in 2026.
• The last three Cash & Equivalents figures came in at $190.0 million (Q1 2026), $165.6 million (Q4 2025), and $174.9 million (Q3 2025), per Business Quant data.